According to the research report, the size of the Europe Multiplex Assays Market is valued at USD 0.77 billion in 2019 and is expected to reach USD 1.1 billion by 2024 at a 7.32% CAGR during the forecast period 2019 to 2024.
While multiplex bead array assays (MBAA) are widely ascribed to be a recent innovation, descriptions of these assays can be found in the literature as far back as 1977. A wide assortment of tests has been devised for MBAA using both immunological and molecular ligands. The potential advantages of these assays are apparent, such as the ability to independently and quantitatively assay multiple analytes simultaneously in small volumes of material and the collection of data from numerous beads for each ligand to provide statistical rigor. The potential cost- and time-savings that could be accrued by use of MBAA in comparison to other methods provides a strong impetus for the routine use of these in both the research and clinical laboratories. As with all clinical laboratory tests, questions of reproducibility, precision, and accuracy must be addressed in order to validate these assays. This commonly involves a comparison to methods considered to be the current standards.
Factors such as increasing number of research & development for treatment of diseases, rising adoption of multiplex assays to reduce operation costs, technological advancements, and growth in adoption of personalized medicine for increasing safety & efficacy of therapies are expected to create new opportunities for the main players during the analysis period. However, lack of experienced healthcare professionals and huge capital investments are the major restrains for the market growth.
This is can be attributed to the increase in the geriatric population, rise in the prevalence of cataract, and rise in the government initiatives to eliminate avoidable blindness. Moreover, rise in adoption of premium lens due to their enhanced visual performance ensures reduced rates of astigmatism, thus boosting the growth of the market. However, unfavorable reimbursement schemes and postoperative complications such as refractive errors are anticipated to have a negative impact on the market growth.
This research report segmented and sub-segmented into the following categories:
Europe accounts for the second largest share of the market. This regional market is driven by the availability of government funds by countries like Germany, France and U.K.
Key players operating in the Europe Multiplex Assays Market profiled in this report are Luminex Corporation, Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Abcam Plc, Becton, Dickinson and Company, Luminex Corporation, Meso Scale Diagnostics, Randox Laboratories Ltd and Seegene Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Consumables
5.1.3 Instruments
5.1.4 Accessories
5.1.5 Software and Services
5.1.6 Y-o-Y Growth Analysis, By Product
5.1.7 Market Attractiveness Analysis, By Product
5.1.8 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Nucleic Acid-Based Multiplex Assays
5.2.2.1 Planar Nucleic Acid Assays
5.2.2.2 Bead-Based Nucleic Acid Assays
5.2.3 Protein-Based Multiplex Assays
5.2.3.1 Planar Protein Assays
5.2.3.2 Bead-Based Protein Assays
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3 Application
5.3.1 Introduction
5.3.2 Research & Development
5.3.2.1 Drug Development
5.3.2.2 Biomarker Discovery and Validation
5.3.3.1 Infectious Diseases
5.3.3.2 Cancer
5.3.3.3 Cardiac Diseases
5.3.3.4 Autoimmune Diseases
5.3.3.5 Alzheimer’s Disease
5.3.3.6 Allergies
5.3.3 Companion Diagnostics
5.3.4 Other Applications
5.3.5 Y-o-Y Growth Analysis, By Application
5.3.6 Market Attractiveness Analysis, By Application
5.3.7 Market Share Analysis, By Application
5.4 Technology
5.4.1 Introduction
5.4.2 Multiplex Pcr
5.4.3 Multiplex Arrays
5.4.3.1 Multiplex Planar Arrays
5.4.3.2 Multiplex Bead-Based Array
5.4.4 Other Technologies
5.4.5 Y-o-Y Growth Analysis, By Technologies
5.4.6 Market Attractiveness Analysis, By Technologies
5.4.7 Market Share Analysis, By Technologies
5.5 End Use
5.5.1 Introduction
5.5.2 Pharmaceutical & Biotechnology Companies
5.5.3 Academic & Research Institutes
5.5.4 Clinical Laboratories
5.5.5 Hospitals
5.5.6 Other End Users
5.4.5 Y-o-Y Growth Analysis, By End Use
5.4.6 Market Attractiveness Analysis, By End Use
5.4.7 Market Share Analysis, By End Use
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Application
6.1.3.5 By Technology
6.1.3.6 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Application
6.1.4.5 By Technology
6.1.4.6 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Application
6.1.5.5 By Technology
6.1.5.6 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Luminex Corporation
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific Inc.
8.3 Illumina Inc.
8.4 Bio-Rad Laboratories Inc.
8.5 QIAGEN N.V.
8.6 Abcam Plc
8.7 Becton
8.8 Dickinson and Company
8.9 Luminex Corporation
8.10 Meso Scale Diagnostics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
